Trulicity, Ozempic, and Mounjaro are three weekly injections used for type 2 diabetes, and they are not interchangeable. Trulicity is dulaglutide and Ozempic is semaglutide, both single-target GLP-1 receptor agonists. Mounjaro is tirzepatide, which acts on two receptors, GLP-1 and GIP, and tends to move blood sugar and weight the most in trials. The right choice usually depends on coverage, dosing tolerance, and what a person is treating, not on brand reputation.
What is actually different about the molecules?
The three sit in two families. Dulaglutide and semaglutide bind the GLP-1 receptor, prompting insulin release when glucose is high, slowing stomach emptying, and reducing appetite. Tirzepatide adds activity at the GIP receptor, and reviews of the mechanism suggest that the dual signal contributes to its larger metabolic effect. The original discovery work on tirzepatide, then labeled LY3298176, was published in 2018 and framed it as a novel dual agonist, and that framing has held up in later trials.
This is not a small taxonomy point. A dual agonist and a single GLP-1 agonist behave differently in the body, which is part of why comparing them by name alone is misleading. Broader work on how these receptor agonists act reinforces that the class is diverse rather than a set of near-copies.
How do they compare on the practical details?
| Brand | Molecule | Targets | Approved use under this brand |
|---|---|---|---|
| Trulicity | Dulaglutide | GLP-1 | Type 2 diabetes |
| Ozempic | Semaglutide | GLP-1 | Type 2 diabetes |
| Mounjaro | Tirzepatide | GLP-1 and GIP | Type 2 diabetes |
All three are once-weekly injections. Trulicity comes in a single-use autoinjector that many people find the simplest to handle, since there is no dose dialing. Ozempic uses a multi-dose pen with a titration schedule. Mounjaro also titrates upward in steps. None of these three carries a separate weight-loss brand: semaglutide’s is sold as Wegovy and tirzepatide’s as Zepbound, while dulaglutide has no weight-management brand at all.
Which one works best, and does that question even make sense?
It half makes sense. On glycemic control and weight, the general ordering from trial data puts tirzepatide highest, semaglutide next, and dulaglutide lower. But these figures come from separate studies with different populations, so lining them up as a direct contest overstates the precision. It is a pattern across the evidence, not a single race.
For a person with type 2 diabetes, the meaningful differences are often smaller than the headlines. Dulaglutide has a long track record and an easy device, and for someone whose numbers are close to target, it may do everything needed. Reaching for the strongest agent when a simpler one would suffice is not automatically the better call, and current obesity pharmacotherapy guidance from 2025 stresses matching the agent to the goal rather than defaulting to the most potent option.
What are these actually treating?
The brand approvals here are for type 2 diabetes, but the reasons people seek them have widened. Updated definitions of clinical obesity have pushed the field to treat excess weight as a condition in its own right rather than a lifestyle failing, and the AGA clinical practice guideline lays out where drug therapy fits alongside diet and activity. There is also growing interest in metabolic liver disease, and the EASL-EASD-EASO guidelines on MASLD discuss where incretin-based therapies sit in that setting. Using Trulicity for weight specifically remains off label, which is worth naming plainly, since its dosing and evidence were built around glucose control.
Where do cost and access decide it?
In practice, the molecule matters less than what a plan will pay for. Many commercial plans cover one or two of these for diabetes but not all three, and formulary placement can force a switch that has nothing to do with clinical preference. Prior authorization is common, and denials are frequently appealable once documentation is complete.
For people paying cash or seeking an off-label route, several telehealth practices publish flat pricing and handle prescribing through licensed clinicians, among them Ro, Hims and Hers, Henry Meds, and LillyDirect. Independent references such as formblends.com break down how dulaglutide compares before any of that spending is committed. Compounded semaglutide and tirzepatide also circulate at lower monthly prices, but they are prepared by compounding pharmacies and are not FDA-approved products, which is a real distinction from the branded drugs and belongs in the decision.
Is the injection era ending?
Partly. An oral small-molecule GLP-1 agonist, orforglipron, reported strong phase results and, per the first-approval record, was approved in 2026 for weight management under the brand FOUNDAYO. Earlier trial data, including a 2023 study and a later obesity trial, showed meaningful weight reduction from a daily pill. That does not replace Mounjaro or the others, but it gives needle-averse patients a real alternative that the three injections here never offered.
Key takeaways
- Trulicity and Ozempic are GLP-1 agonists; Mounjaro adds GIP activity, which drives its larger effect.
- The strength ranking comes from separate trials, not one head-to-head, so treat it as a pattern.
- All three are approved for diabetes; using dulaglutide for weight is off label.
- Coverage and device preference decide the choice more often than potency does.
- Compounded versions are not FDA-approved, and an oral option now exists for weight management.
Frequently asked questions
Are all three the same kind of drug?
Not quite. Trulicity (dulaglutide) and Ozempic (semaglutide) are GLP-1 receptor agonists. Mounjaro (tirzepatide) acts on both the GLP-1 and the GIP receptors, which is why it is described as a dual agonist rather than a single-target GLP-1.
Which one leads to the most weight change?
Across separate trials, tirzepatide has shown the largest average weight reduction, followed by semaglutide, with dulaglutide generally lower. These come from different studies rather than one head-to-head, so the ranking is a pattern, not a precise league table.
Are these approved for weight loss or for diabetes?
All three are approved for type 2 diabetes under these brand names. Semaglutide and tirzepatide also have separate weight-management brands. Dulaglutide does not have a weight-loss brand, so its use for weight is off label.
Is compounded semaglutide or tirzepatide the same as the brand?
No. Compounded versions are prepared by compounding pharmacies and are not FDA-approved products. They may contain the same active molecule, but they have not gone through the approval process behind the trial evidence for the brands.
Does an oral option change the picture?
It can. Orforglipron, an oral small-molecule GLP-1 agonist, was approved in 2026 for weight management, which introduces a pill into a field that was previously all injections. That matters for people who avoid needles.
